The FDA has approved Otarmeni (lunsotogene parvec-cwha), marking a significant advancement as the first dual adeno-associated virus (AAV) vector-based gene therapy for the treatment of severe-to-profound sensorineural hearing loss linked to biallelic variants in the OTOF gene. This approval comes just 61 days post-BLA filing, making it one of the fastest in FDA history and the first gene therapy product approved under the Commissioner’s National Priority Voucher (CNPV) pilot program. The therapy is specifically indicated for patients with preserved outer hair cell function and no prior cochlear implant in the affected ear.

The significance of Otarmeni lies in its mechanism of action and the clinical outcomes observed in trials. The therapy delivers a functional copy of the OTOF gene directly to inner hair cells, restoring otoferlin production, which is crucial for sound signal transmission. In a multi-center clinical trial involving 24 pediatric patients, 80% of evaluable participants demonstrated improved hearing, a result not typically expected without intervention in the natural history of OTOF-related deafness. This is particularly noteworthy given that genetic mutations account for approximately half of congenital hearing loss, with OTOF variants representing a substantial subset.

The implications of this approval extend beyond immediate clinical applications; it may reshape research paradigms in gene therapy for genetic hearing loss and other rare diseases. The rapid approval process under the CNPV program highlights the FDA’s commitment to expediting therapies for conditions with unmet medical needs, potentially influencing future drug development timelines and regulatory strategies. Continued assessment of Otarmeni’s effectiveness will focus on the durability of hearing improvements and impacts on speech development and quality of life, setting a precedent for future gene therapies in similar contexts.

Source: globenewswire.com